Showing results (61-70 of 107) with videos related to
Sort By:
Pageof 11
Clinical Breast Cancer|May 22, 2012
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expressionEvangelia Razis, Konstantine T Kalogeras, Vassiliki Kotoula, et al.Histology and Histopathology|March 26, 2015
Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) studyHelen P Kourea, Vassiliki Kotoula, Angelos Koutras, et al.Anticancer Research|July 1, 2015
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group TrialHelena Linardou, Konstantine T Kalogeras, Ralf Kronenwett, et al.Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.Cancers|June 2, 2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, et al.Journal of Translational Medicine|May 18, 2016
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerHelen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, et al.Journal of Translational Medicine|May 30, 2015
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation studyAngelos Koutras, Konstantine T Kalogeras, Ralph M Wirtz, et al.Cancer Genomics & Proteomics|October 22, 2018
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with TrastuzumabChristos Christodoulou, Georgios Oikonomopoulos, Georgia Angeliki Koliou, et al.Anticancer Research|April 4, 2021
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast CancerGeorgios Rigakos, Evangelia Razis, Georgia-Angeliki Koliou, et al.Cancer Research and Treatment|November 18, 2021
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based RegimensHelen P Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, et al.Pageof 11